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ABSTRACT
A variety of serine proteases, including urokinase-type plasminogen
activator (uPA), plasmin, and polymorphonuclear leukocyte elastase
(PMN-E), have been implicated in the processes of tumor cell invasion and
metastasis. Besides degrading of matrix proteins, PMN-E has been shown
to be able to cleave and inactivate plasminogen activator inhibitor-1
(PAI-1), the main inhibitor of uPA, and 2-antiplasmin, the natural
inhibitor of plasmin, thus enabling an uncontrolled matrix degradation by
the fibrinolytic enzymes. Because only limited data are available on a
relationship between the tumor level of PMN-E and prognosis in primary
breast cancer patients, in the present study we have measured with an
ELISA the levels of PMN-E (in complex with 1-proteinase inhibitor) in
cytosolic extracts of 1143 primary breast tumors. Levels of complexed
PMN-E have been correlated with the lengths of metastasis-free survival
(MFS), relapse-free survival, and overall survival, and a comparison was
made with data previously obtained for uPA and PAI-1. Our results show
that patients with a high PMN-E level in their primary tumor had a rapid
relapse and an early death compared with patients with a low tumor level
of PMN-E. This held true for node-negative and node-positive subgroups
of patients as well. The relationship of PMN-E with a poor prognosis was
especially obvious during short-term follow-up (0–60 months). In Cox
multivariate regression analysis, corrected for the traditional prognostic
factors, PMN-E was an independent prognostic factor, and high levels of
PMN-E were associated with a poor MFS [hazard ratio (HR), 1.63; 95%
confidence interval (CI), 1.23–2.16; P < 0.001], relapse-free survival (HR,
1.45; 95% CI, 1.10–1.89; P  0.01), and overall survival (HR, 1.64; 95%
CI, 1.20–2.23; P  0.003). Furthermore, in all three multivariate models,
PMN-E still added significantly to the model after the additional inclusion
of the uPA. PMN-E was an independent prognostic factor for MFS even
in the multivariate analysis including the traditional clinical prognostic
factors and the strong established biochemical prognostic factors uPA and
PAI-1. Our present study suggests that PMN-E is associated with breast
cancer metastasis, and knowledge of the tumor PMN-E status might be
helpful in selecting the appropriate individualized (adjuvant) treatment
for patients with breast cancer.
INTRODUCTION
The serine protease uPA3 and its main inhibitor, PAI-1, have been
studied extensively for their prognostic value in patients with breast
cancer, indicating that high tumor levels of both parameters are
associated with a poor prognosis (1, 2). The finding of a relationship
between high levels of the inhibitor PAI-1 and a poor prognosis can
be attributed to its role as a direct enhancer of adhesion, migration,
and tumor angiogenesis irrespective of its protease inhibitor potency
(3, 4).
PAI-1 can be cleaved by the serine protease PMN-E, produced
mainly in polymorphonuclear leukocytes, thereby loosing its inhibi-
tory activity against uPA (5). Furthermore, PMN-E has been shown to
inactivate 2-antiplasmin, the natural inhibitor of the serine protease
plasmin (6). Because PMN-E itself disintegrates matrix proteins such
as elastin, collagen, and proteoglycans (7), a prominent role of
PMN-E seems to be very likely in the process of tumor cell invasion
and metastasis. Interestingly, PMN-E is produced not only by neutro-
phils but also by human breast cancer cells in cell culture (8).
Although the main origin of PMN-E in tumor tissue extracts is not yet
clear, the first pilot studies measuring PMN-E in tissue extracts of
human breast cancer samples revealed a clear relation between ele-
vated elastase levels and poor prognosis of the patients (9, 10).
Because PMN-E and the fibrinolysis parameters interact, we con-
sidered it of interest to evaluate the combined prognostic value of
PMN-E, uPA, and PAI-1 in primary breast cancer patients (n 1143).
The findings were correlated with the patient and tumor characteris-
tics as well as with traditional clinical prognostic factors, revealing
PMN-E as an independent prognostic parameter for MFS when tested
in the multivariate analysis.
MATERIALS AND METHODS
Patients and Tissue Samples. PMN-E levels were determined in cytosol
preparations (as described below) from 1143 primary invasive breast tumors
collected between 1978 and 1989. Our study design was approved by the
medical ethical committee of the Erasmus University (Rotterdam, the Nether-
lands). Inoperable T4 tumors and tissue specimens that were sampled after
neoadjuvant treatment or obtained from a biopsy were excluded. Furthermore,
patients admitted to our institute more than 100 days after primary surgery and
patients with distant metastasis at the time of primary surgery [M1 patients;
staging according to the International Union Against Cancer tumor-node-
metastasis (TNM) classification] were excluded.
Median age of the patients at the time of surgery (modified mastec-
tomy 615 patients, breast-conserving treatment 528 patients) was 56 years
(range, 27–90 years). The characteristics of the patients with respect to men-
opausal status, tumor size, nodal status, tumor histology and grade, and ER and
PgR status are listed in Table 1. Radiotherapy was applied to 1006 patients
(88%): on the breast/thoracic wall in 788 patients and/or on the axilla in 430
patients; and/or parasternal and/or supraclavicular lymph nodes in 516 patients.
None of the node-negative patients received systemic adjuvant therapy. Ad-
juvant chemotherapy [mainly cyclophosphamide/methotrexate/5-fluorouracil
(CMF)] was given to 213 node-positive patients (mainly premenopausal
patients), whereas 58 patients received adjuvant hormonal therapy (mainly
postmenopausal patients), either alone (44 patients) or in combination with
chemotherapy (14 patients).
All patients were examined routinely every 3–6 months during the first 5
years of follow-up and once a year thereafter. The median follow-up period of
patients alive (n 584) was 124 months (range, 13–231 months). Patients with
events after 120 months were censored at 120 months because after 10 years
of observation, patients frequently are redirected to their general practitioner
for checkups and mammography and cease to visit our outpatient breast cancer
clinic. Of the 1143 patients included, 629 (55%) showed evidence of disease
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(including locoregional relapse) and count as failures in the analysis of RFS.
In the analysis of MFS, 538 (47%) patients with distant metastasis were
counted as failures. Sixty patients (5%) died without evidence of disease and
were censored at last follow-up in the analysis of RFS and MFS. Four hundred
and fifty-one (39%) patients died after a previous relapse. Thus, a total of 511
patients (45%) were failures in the analysis of OS.
Assays of ER, PgR, Total Protein, uPA, PAI-1, and PMN-E in Tumor
Tissue Extracts. Processing of tumor tissues as recommended by the EORTC
for cytosolic ER and PgR determinations by ligand binding assay or with
enzyme immunoassay was as described previously (11). Total cytosolic protein
was quantified with the Coomassie Brilliant Blue method (Bio-Rad) with
human serum albumin as a standard. The cytosolic levels of uPA and PAI-1
were determined with ELISAs as described previously (12).
Taking into account that most of the PMN-E in body fluids or tissue
cytosols is complexed with its main antagonist, 1PI, we used a commercial
two-site ELISA for quantification of the complex (Milenia-PMN Elastase;
Milenia Biotec, Bad Nauheim, Germany). For measurement of the total
amount of the enzyme, presumably free, proteolytically active elastase was
complexed by adding a surplus of 1PI (100 g/ml) to an aliquot of each
cytosol, and the sample was reassayed for an increase in the elastase-1PI
complex. Free PMN-E was defined as the amount of PMN-E measured in the
presence of additional 1PI minus that measured in the original sample.
Because total PMN-E and free PMN-E were significantly correlated with each
other (Spearman rank correlation, rs 0.54; P 0.001), we have restricted the
data presentation to total PMN-E. Moreover, the PMN-E levels in cytosols
significantly (rs  0.85; P  0.001) correlated with those quantified in Triton
X-100 extracts prepared according to Ja¨nicke et al. (13). In the present study,
we have used cytosol for total PMN-E determination. The EORTC receptor
buffer used to prepare the cytosols did not interfere with the ELISA determi-
nation of PMN-E. This was checked by dilution of the elastase standard protein
in EORTC buffer instead of calibrator diluent. The coefficients of variation
were calculated from different samples in a total of 42 runs, demonstrating a
mean intra- and interassay coefficient of variation CV of 2.6% and 6.4%,
respectively.
Statistics. The strength of the associations of PMN-E with continuous
variables was tested with Spearman rank correlation. The strength of the
association of PMN-E with other variables (used as grouping variable) was
tested with the nonparametric Wilcoxon rank-sum test or Kruskal-Wallis test,
followed by a Wilcoxon-type test for trend across ordered groups where
appropriate. Survival probabilities were calculated by the actuarial method of
Kaplan and Meier. Both univariate and multivariate analyses were performed
using the Cox proportional hazards model. The likelihood ratio test in the Cox
Fig. 1. MFS (A), RFS (B), and OS (C) as a function of total PMN-E status in 1143
primary breast cancer patients. Patients at risk are indicated. Cut point used, 36.4 ng
PMN-E/mg protein.






All patients 1143 6.6 (3.6, 13.5)
Age (yrs) 0.01c
40 161 7.8 (4.3, 19.8)
41–55 382 6.6 (3.5, 13.4)
56–70 406 6.2 (3.3, 12.3)
70 194 6.5 (3.7, 12.8)
Menopausal status 0.03d
Premenopausal 457 6.8 (3.8, 16.3)
Postmenopausal 686 6.4 (3.4, 12.6)
T status 0.58e
T  2 cm 460 6.2 (3.5, 13.0)
T  2–5 cm 546 6.7 (3.8, 14.7)
T  5 cm 137 7.1 (3.3, 14.2)
N status 0.45e
N0 475 6.7 (3.7, 14.6)
N1–3 332 6.2 (3.4, 12.9)
N3 336 6.7 (3.5, 12.9)
Histology
Intraductal 789 6.7 (3.6, 14.1) 0.001e
Intralobular 48 4.4 (2.8, 7.5)
Mucinous 23 5.2 (3.5, 7.9)
Medullary 29 16.3 (8.0, 96.6)
Others  unknown 254 6.6 (3.6, 13.5)
Histological grade 0.07e
Poor 636 6.8 (3.9, 15.1)
Moderate 206 6.3 (3.5, 11.6)
Good 15 3.9 (2.4, 8.4)
ER statusf 0.001f
Negative 244 14.9 (6.1, 41.7)
Positive 896 5.8 (3.3, 10.3)
PgR statusf 0.001c
Negative 321 9.1 (5.2, 30.3)
Positive 796 6.0 (3.3, 10.7)
a Due to missing values, numbers do not always add up to 1143.
b All values in ng/mg of protein (25th and 75th percentiles).
c P for Spearman rank correlation.
d P for Wilcoxon rank-sum test.
e P for Kruskal-Wallis test.
f Cut points used for ER and PgR: 10 fmol/mg of protein.
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regression models was used to test for differences and for interactions. In our
search for a categorization of PMN-E, we used IRA (11, 14). With IRA, the
hazard rate for failure is estimated as a function of the PMN-E value under the
assumption of a monotone increasing failure rate with increasing PMN-E
levels. The patients are ordered according to the PMN-E level and subse-
quently partitioned in ordered groups in such a way that average failure rates
in the groups increase with increasing PMN-E level. The final partition is
optimal in the sense that it is the maximum likelihood estimate for the
exponential failure model. The cut point will be identified where the jump in
the failure rates or the average time to failure is largest. The proportionality
assumption was investigated using a test based on the Schoenfeld residuals
(15). The residuals are retrieved, and a smooth function of time is fitted and
then tested to determine whether there is a relationship. All computations were
done with the STATA statistical package, release 7.0 (STATA Corp., College
Station, TX). All Ps are two-sided.
RESULTS
PMN-E Levels in Relation to Patient and Tumor Characteris-
tics and uPA/PAI-1 Levels. The levels of PMN-E in 1143 tumor
cytosols ranged from 0.4 to 1667 ng/mg protein (median, 6.6 ng/mg
protein). Table 1 shows the median and the 25th and 75th percentile
levels of PMN-E in subgroups of tumors and their relationship with
patient and tumor characteristics. The tumor level of PMN-E was
higher in premenopausal patients and was negatively related with age
(rs  0.07), ER (rs  0.28), and PgR (rs  0.23). Compared
with intraductal carcinomas, medullary tumors contained higher levels
of PMN-E, and intralobular and mucinous tumors contained lower
levels of PMN-E. There were no significant correlations with tumor
size, lymph node status, or histological grade, whereas PMN-E levels
were positively correlated with those of uPA (rs  0.17) and PAI-1
(rs  0.30).
MFS, RFS, and OS: Univariate Analysis. When studying
PMN-E as a categorized variable divided in quartiles in Kaplan-Meier
survival analyses, we noticed that the curves merged and occasionally
crossed after 10 years of follow-up. This can be interpreted as a
violation of the proportional hazards assumption during long-term
prognosis and was confirmed when we checked the proportional
hazards assumption for MFS (2  8.9, d.f.  1, P  0.003), RFS
(2  11.3, d.f.  1, P  0.001), and OS (2  14.7, d.f.  1,
P  0.001). MFS, RFS, and OS analyses as a function of continuous
PMN-E levels showed a significant relationship with a poor prognosis
(P  0.02, P  0.01, and P  0.001, respectively) during short-term
observation (0–60 months), whereas the proportional hazards as-
sumption was no longer violated for MFS (P  0.14), RFS
(P  0.07), or OS (P  0.22). We therefore restricted our analysis to
short-term prognosis.
The significant inverse relationship of continuous PMN-E levels
with prognosis justified the search for a cut point to allow visualiza-
tion with survival curves and analysis as a categorical variable in
addition to analysis of PMN-E as a continuous variable. Using the
results of the IRA with short-term MFS, RFS, and OS as end points,
we chose 36.4 ng PMN-E/mg protein as a cut point to classify tumors
as PMN-E-low and PMN-E-high. The Kaplan-Meier curves for all
patients as a function of PMN-E status show that high levels of
PMN-E were significantly associated with a poor MFS (Fig. 1A), RFS
(Fig. 1B), and OS (Fig. 1C).
In separate analyses, we explored the prognostic value of PMN-E in
Fig. 2. MFS (A and B), RFS (C and D), and OS
(E and F) as a function of total PMN-E status in
subgroups of node-negative (A, C, and E) and
node-positive patients (B, D, and F). Cut point
used, 36.4 ng PMN-E/mg protein. Patients at risk
are indicated.
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the clinically relevant subgroups of node-negative and node-positive
patients. The results of the Kaplan-Meier analyses and log-rank tests
again provided evidence that PMN-E was a stronger prognostic factor
during short-term follow-up. This difference in HR between short-
term and long-term follow-up was less pronounced for node-positive
patients than for node-negative patients (Fig. 2).
MFS, RFS, and OS: Multivariate Analysis. The independent
relationship of PMN-E with MFS, RFS, and OS was studied with Cox
multivariate regression analysis during short-term follow-up. In the
analysis of all patients, tumor size, nodal status, and young premeno-
pausal age were associated with poor prognosis. In all three models,
PgR positivity was associated with a favorable prognosis, whereas ER
did not significantly add to the models of MFS and RFS. Tumor
grade, which was a significant prognostic factor in both short-term
and long-term univariate analyses of MFS, RFS, and OS (all
P  0.05), did not significantly contribute to any of the multivariate
models. The multivariate model including age and menopausal status,
tumor size, nodal status, ER, and PgR was defined as the base model
(Table 2).
After inclusion of PMN-E as a dichotomized variable to the mul-
tivariable models, the increase in 2 (2) was 10.6 (d.f.  1) in the
analyses of MFS (P  0.001), 6.7 (d.f.  1) in the analysis of RFS
(P  0.01), and 8.9 (d.f.  1) in the analyses of OS (P  0.003).
Analysis of PMN-E as a continuous variable only showed a signifi-
cant contribution to the base model for OS (2  8.4, d.f.  1,
P  0.004). When PMN-E was added as a dichotomized variable to
the base models including the established strong prognostic factor
uPA as well, PMN-E still significantly contributed to the multivariate
models for MFS (2  7.7, d.f.  1, P  0.005), RFS (2  4.5,
d.f.  1, P  0.04), and OS (2  6.9, d.f.  1, P  0.009).
Additional inclusion of PAI-1 to these multivariate models resulted
only in a better fit of PMN-E in the model for MFS (2  3.9,
P  0.048), whereas both uPA and PAI-1 were independent prog-
nostic factors in all three models (Table 2).
Addition of adjuvant treatment as an indicator variable to the
models did not change the coefficients of PMN-E. Furthermore, there
were no statistically significant interactions between PMN-E and any
of the other prognostic factors in any of the analyses. Moreover, after
defining the final multivariate models for short-term prognosis, the
proportional hazards assumption of PMN-E, either as a continuous or
as a categorical variable, was not violated.
DISCUSSION
To identify the 60–70% of node-negative patients who do not need
adjuvant treatment or to select node-positive patients who may be
candidates for more aggressive and/or specific forms of treatment, the
use of traditional prognostic factors is not sufficient. Therefore, the
identification of prognostic factors that reflect the biology of breast
cancer is important.
Proteases and their inhibitors have turned out to be essential for the
invasive and metastatic capability of tumor cells. In this respect, the
serine protease uPA and its inhibitor, PAI-1, have been studied
extensively, especially in breast cancer, showing a clear relation with
a poor prognosis. Recently, two level-of-evidence 1 type studies
[according to proposed guidelines (16)] have unequivocally demon-
strated the prognostic value of uPA and PAI-1 in node-negative (1, 2)
and node-positive breast cancer (2).
PMN-E, a serine protease produced by polymorphonuclear leuko-
cytes and breast cancer cells (8, 17), showed prognostic value in
breast cancer (8–10). PMN-E may play a role in the urokinase system
of plasminogen activation by affecting uPA-governed plasmin pro-
Table 2 Cox multivariate analysis of MFS, RFS, and OSa
Factor
MFS RFS OS
HRb P HRb P HRb P
Base model
Age and menopausal statusc 0.03 0.005 0.001
Age premenopausald 0.73 (0.57–0.92) 0.68 (0.55–0.85) 0.63 (0.47–0.85)
Age postmenopausald 0.91 (0.79–1.05) 0.96 (0.84–1.09) 1.08 (0.93–1.25)
Post- vs. premenopausal 1.70 (1.15–2.52) 1.83 (1.27–2.64) 2.27 (1.38–3.73)
Tumor size 0.001 0.001 0.001
2–5 cm vs. 2 cm 1.71 (1.35–2.17) 1.69 (1.36–2.10) 1.69 (1.27–2.24)
5 cm vs. 2 cm 2.47 (1.81–3.36) 2.31 (1.73–3.10) 2.57 (1.82–3.63)
Nodal status 0.001 0.001 0.001
N1–3 vs. N0 1.80 (1.37–2.35) 1.66 (1.30–2.11) 2.41 (1.73–3.35)
N3 vs. N0 3.23 (2.50–4.17) 2.75 (2.18–3.47) 4.00 (3.22–6.02)
ER (positive vs. negative)e 0.94 (0.72–1.22) 0.62 0.87 (0.68–1.11) 0.25 0.72 (0.54–0.96) 0.02
PgR (positive vs. negative)e 0.67 (0.53–0.85) 0.001 0.76 (0.61–0.95) 0.02 0.57 (0.44–0.74) 0.001
Additions to base modelf
PMN-E (high vs. low)g,h 1.63 (1.23–2.16) 0.001 1.45 (1.10–1.89) 0.01 1.64 (1.20–2.23) 0.003
PMN-E (continuous)g,i 1.06 (0.98–1.15) 0.16 1.06 (0.98–1.14) 0.13 1.14 (1.05–1.25) 0.004
PMN-E  uPA  PAI-1j
PMN-E (high vs. low)h 1.36 (1.01–1.82) 0.048 1.22 (0.92–1.62) 0.17 1.32 (0.96–1.82) 0.10
uPAk 0.001 0.001 0.002
Intermediate vs. low 1.66 (1.20–2.30) 1.45 (1.09–1.94) 1.51 (1.04–2.19)
High vs. low 2.29 (1.61–3.28) 1.99 (1.45–2.73) 2.02 (1.35–3.03)
PAI-1l 0.03 0.02 0.003
Intermediate vs. low 1.23 (0.92–1.65) 1.28 (0.98–1.67) 1.16 (0.82–1.63)
High vs. low 1.78 (1.17–2.69) 1.76 (1.19–2.60) 2.06 (1.30–3.26)
a Final multivariate models included 1116 patients; follow-up truncated at 60 months.
b Numbers in parentheses, 95% CI.
c Age and menopausal status combined.
d Age in decades for pre- and postmenopausal patients.
e Positive, 10 fmol/mg protein; negative 10 fmol/mg protein.
f Factors added alone or together to the base model.
g PMN-E added alone to the base model.
h High, 36.4 ng/mg protein; low, 36.4 ng/mg protein.
i Log-transformed variable.
j PMN-E, uPA, and PAI-1 added together to the base model.
k Low, 0.19 (n  244); intermediate, 0.19 and 1.21 (n  550); high, 1.21 ng/mg of protein (n  322) (for cut points, Ref. 12).
l Low, 9.33 (n  294); intermediate, 9.33 and 45.28 (n  729); high, 45.28 ng/mg of protein (n  93) (for cut points, Ref. 12).
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duction (18), by cleaving the inhibitor PAI-1 (5), or by inactivating
2-antiplasmin, the main inhibitor of plasmin (6). Therefore, we
studied the prognostic value of PMN-E combined with those of uPA
and PAI-1. To our knowledge, thus far, no other reports have analyzed
PMN-E, uPA, and PAI-1 levels together.
In our present study, tumor PMN-E levels were positively corre-
lated with those of uPA and PAI-1, consistent with the known com-
plex interactions between various proteases and inhibitors. Higher
tumor levels of PMN-E were associated with a poor MFS, RFS, and
OS in a large series of primary breast cancer patients. The propor-
tional hazards assumption (that is, the effect of PMN-E over time) was
violated when the total follow-up period of 120 months was used.
Similar changes over time have been reported for several traditional
prognostic factors in breast cancer (19). When used as a dichotomized
variable in short-term MFS, RFS, and OS (60 months), during which
period the proportional hazards assumption was not violated, the
prognostic value of PMN-E was independent of that of the traditional
prognostic factors age, menopausal status, tumor size, tumor grade,
nodal status, and steroid hormone receptor status and even of the
established strong prognostic factor uPA. Although uPA and PAI-1
appeared to be stronger prognostic factors than PMN-E, the observed
prognostic value of PMN-E, independent of traditional prognostic
factors, is in accordance with the data reported previously by
Yamashita et al. (8–10) in studies in which up to 313 patients were
included.
However, in contrast to Yamashita et al. (9), we could not demon-
strate that only free-form elastase independently predicts recurrence in
primary breast cancer. In our study, about 35% of all samples exhib-
ited free elastase. Although the ratio of free-form to total immunore-
active elastase varied over a wide range between 5% and 95%, similar
to the results of Yamashita et al. (9), the prognostic potency of active
elastase was comparable with that of total elastase (data not shown).
Taking into consideration that the pool of free-form elastase in cy-
tosols of tumor tissues depends not only on the overall content of
elastase in tumor cells and infiltrating polymorphonuclear leukocytes
but even more on the amount of 1PI in the stroma, it seems more
rational to us to evaluate the prognostic potency of total elastase (after
the addition of exogenous 1PI) in tumor tissue samples than to focus
on free-form elastase.
In the primary breast tumors, PMN-E levels were negatively cor-
related with those of ER and PgR. This was not reported in previous
studies (8, 10), but direct comparison is not possible due to differences
in assays and tumor extracts used, methods of reporting the statistical
data, and the number of patients included.
Taking together our data and those of other authors, various com-
plex proteolytic systems seem to play a role in tumor progression.
There is a large redundancy among protease systems, suggesting that
if one or more protease systems fail, other systems may be able to take
over their (pathological) physiological role. Together with or separate
from other protease systems, PMN-E seems to play a role in breast
cancer metastasis in a relatively small subgroup of patients. Breast
cancer is very heterogeneous disease, and individual risk assessment
based on a specific tumor phenotype may be particularly helpful for
small subgroups of patients to design individualized tailored treatment
strategies. Therefore, knowledge of the PMN-E status of the primary
tumor may be helpful in a detailed assessment of prognosis. Further-
more, the development of neutrophil elastase inhibitors (20) may
eventually lead to novel targeted (combination) therapies for specific
groups of primary and advanced breast cancer patients expressing a
high level of PMN-E in their tumor.
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